Article Text

Download PDFPDF
Administration of mesenchymal stem cells during ECMO results in a rapid decline in oxygenator performance
  1. Jonathan Edward Millar1,
  2. Viktor von Bahr1,2,
  3. Maximillian V Malfertheiner1,3,
  4. Katrina K Ki1,
  5. Meredith A Redd4,
  6. Nicole Bartnikowski1,
  7. Jacky Y Suen1,
  8. Danny Francis McAuley5,
  9. John F Fraser1
  1. 1 Critical Care Research Group, University of Queensland, Brisbane, Queensland, Australia
  2. 2 Department of Physiology and Pharmacology, Section for Anesthesiology and Intensive Care Medicine, Karolinska Institutet, Stockholm, Sweden
  3. 3 Department of Internal Medicine II, Cardiology and Pneumology, University Medical Center Regensburg, Regensburg, Germany
  4. 4 Institute for Molecular Bioscience, University of Queensland, Brisbane, Queensland, Australia
  5. 5 Queen’s University Belfast, Wellcome-Wolfson Centre for Experimental Medicine, Belfast, UK
  1. Correspondence to Dr Jonathan Edward Millar, Critical Care Research Group, University of Queensland, The Prince Charles hospital, Brisbane QLD 4032, Australia ; j.millar{at}doctors.org.uk

Footnotes

  • Contributors JEM, DFM and JFF conceived and designed the study. VvB and MVM designed and modified the ex-vivo ECMO model. JEM, VvB and MVM conducted the ex-vivo experiments. KKK, MAR, NB and JYS analysed the generated samples. All authors have participated in the drafting and critical revision of the manuscript.

  • Funding This study was supported by the Intensive Care Society (UK) New Investigator Award and by the National Health and Medical Research Council (NHMRC), Australia (APP1079421). VvB is funded by Gålöstiftelsen Foundation, Olle Enqvist Byggmästare Foundation, Karolinska Institutet Fernström Foundation, and the Royal Swedish Academy of Sciences, Claes Adelsköld Foundation.

  • Competing interests Cynata Therapeutics provided mesenchymal stem cells in kind to this study. The company was not involved in the commission, design or analysis of the study.

  • Ethics approval The study was approved by the Metro North Ethics Committee (HREC/16/QPCH/221).

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Correction notice This article has been corrected since it was published Online First. Errors with in Table 1 was corrected.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors JEM, DFM and JFF conceived and designed the study. VvB and MVM designed and modified the ex-vivo ECMO model. JEM, VvB and MVM conducted the ex-vivo experiments. KKK, MAR, NB and JYS analysed the generated samples. All authors have participated in the drafting and critical revision of the manuscript.

  • Funding This study was supported by the Intensive Care Society (UK) New Investigator Award and by the National Health and Medical Research Council (NHMRC), Australia (APP1079421). VvB is funded by Gålöstiftelsen Foundation, Olle Enqvist Byggmästare Foundation, Karolinska Institutet Fernström Foundation, and the Royal Swedish Academy of Sciences, Claes Adelsköld Foundation.

  • Competing interests Cynata Therapeutics provided mesenchymal stem cells in kind to this study. The company was not involved in the commission, design or analysis of the study.

  • Ethics approval The study was approved by the Metro North Ethics Committee (HREC/16/QPCH/221).

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Correction notice This article has been corrected since it was published Online First. Errors with in Table 1 was corrected.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.